Amicus Therapeutics, Inc. $FOLD Shares Sold by Prudential Financial Inc.

Prudential Financial Inc. trimmed its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 36.1% during the second quarter, Holdings Channel reports. The firm owned 273,594 shares of the biopharmaceutical company’s stock after selling 154,355 shares during the period. Prudential Financial Inc.’s holdings in Amicus Therapeutics were worth $1,568,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Nuveen LLC acquired a new position in shares of Amicus Therapeutics during the first quarter valued at $28,741,000. Assenagon Asset Management S.A. lifted its position in Amicus Therapeutics by 641.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 3,533,854 shares of the biopharmaceutical company’s stock valued at $20,249,000 after purchasing an additional 3,057,072 shares during the last quarter. Millennium Management LLC lifted its position in Amicus Therapeutics by 635.1% in the 1st quarter. Millennium Management LLC now owns 3,359,389 shares of the biopharmaceutical company’s stock valued at $27,413,000 after purchasing an additional 2,902,375 shares during the last quarter. Redmile Group LLC boosted its stake in Amicus Therapeutics by 35.1% during the 1st quarter. Redmile Group LLC now owns 9,533,669 shares of the biopharmaceutical company’s stock valued at $77,795,000 after purchasing an additional 2,478,779 shares during the period. Finally, M&G PLC acquired a new position in Amicus Therapeutics during the 2nd quarter valued at about $11,310,000.

Amicus Therapeutics Stock Performance

Shares of NASDAQ FOLD opened at $9.90 on Friday. Amicus Therapeutics, Inc. has a 1 year low of $5.51 and a 1 year high of $10.57. The firm has a market cap of $3.05 billion, a P/E ratio of -247.44 and a beta of 0.46. The stock has a fifty day moving average price of $8.94 and a two-hundred day moving average price of $7.51. The company has a debt-to-equity ratio of 1.70, a quick ratio of 2.09 and a current ratio of 2.99.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.05. The business had revenue of $169.06 million during the quarter, compared to analyst estimates of $165.24 million. Amicus Therapeutics had a positive return on equity of 6.95% and a negative net margin of 2.35%.The company’s revenue was up 19.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.10 earnings per share. Research analysts forecast that Amicus Therapeutics, Inc. will post 0.15 EPS for the current fiscal year.

Insider Buying and Selling at Amicus Therapeutics

In other news, insider Ellen Rosenberg sold 23,621 shares of the stock in a transaction on Wednesday, November 26th. The stock was sold at an average price of $10.00, for a total transaction of $236,210.00. Following the completion of the sale, the insider owned 507,710 shares in the company, valued at approximately $5,077,100. This represents a 4.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jeff Castelli sold 76,158 shares of the firm’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $10.16, for a total value of $773,765.28. Following the sale, the insider directly owned 439,318 shares of the company’s stock, valued at approximately $4,463,470.88. This represents a 14.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 216,239 shares of company stock valued at $2,165,304 over the last quarter. Company insiders own 2.20% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on FOLD. JPMorgan Chase & Co. lifted their price target on Amicus Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Zacks Research upgraded Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. The Goldman Sachs Group boosted their price target on Amicus Therapeutics from $9.00 to $11.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 5th. Needham & Company LLC raised Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a report on Thursday, September 18th. Finally, Wall Street Zen raised shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $16.57.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.